Clinical Trials Logo

Adenoid Cystic Carcinoma clinical trials

View clinical trials related to Adenoid Cystic Carcinoma.

Filter by:

NCT ID: NCT06462183 Not yet recruiting - Colorectal Cancer Clinical Trials

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Start date: June 2024
Phase: Phase 1
Study type: Interventional

Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRCT

NCT ID: NCT06322576 Not yet recruiting - Clinical trials for Adenoid Cystic Carcinoma

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Start date: July 2024
Phase: Phase 2
Study type: Interventional

This is a single arm trial with one Cohort for people with recurrent or metastatic adenoid cystic carcinoma that cannot be treated with surgery. 10 participants will be enrolled in Cohort 1 at Johns Hopkins and will undergo DCFPyL PET/CT and 177Lu-PSMA dosimetry imaging only (single tracer dose). A feasibility analysis of dosimetry will be performed after meeting the accrual goal of Cohort 1 to determine if the study will proceed into Cohort 2. If Cohort 2 proceeds, based on the dosimetry analysis, the major requirements of the study are to undergo treatment with 177Lu-PNT2002, have bloodwork, physical exams, and imaging done at study-specific time points, and to answer questionnaires. Patients will be in the study for about two years after enrolling.

NCT ID: NCT06199453 Not yet recruiting - Clinical trials for Adenoid Cystic Carcinoma

The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients With ACC- an Open, Non-commercial Clinical Trial

LuRM_ACC/2023
Start date: January 2024
Phase: Phase 2
Study type: Interventional

Non-commercial phase 2 clinical trial to evaluate the effectiveness, safety and tolerability of treatment using prostate-specific membrane antigen (PSMA) labeled with 177Lutetium in patients with recurrence and/or metastases in adenoid cystic carcinoma originating from the salivary glands of the head and neck region. Patients with PSMA receptor expression confirmed by PET/CT after administration of 68Ga-PSMA I&T will be eligible for treatment.

NCT ID: NCT06118086 Recruiting - Clinical trials for Adenoid Cystic Carcinoma

Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Start date: December 20, 2023
Phase: Phase 1
Study type: Interventional

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)

NCT ID: NCT05774899 Recruiting - Clinical trials for Adenoid Cystic Carcinoma

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Start date: June 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes. The names of the study drugs involved in this study are: - CB-103 (an oral NOTCH pathway inhibitor) - Abemaciclib (CDK4/6 inhibitor) - Lenvatinib (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI))

NCT ID: NCT05553782 Not yet recruiting - Clinical trials for Adenoid Cystic Carcinoma

Drug Screening Using Novel IMD in ACC and Salivary Cancers

Start date: November 1, 2023
Phase: Early Phase 1
Study type: Interventional

This research study is studying the effect of different drugs as possible treatments for adenoid cystic carcinoma (ACC), a type of head and neck cancer. The name of the study intervention involved in this study is: -implantable microdevice

NCT ID: NCT05377996 Recruiting - Breast Cancer Clinical Trials

A Study of XMT-1660 in Participants With Solid Tumors

Start date: August 15, 2022
Phase: Phase 1
Study type: Interventional

A Study of XMT-1660 in Solid Tumors

NCT ID: NCT05194072 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of SGN-B7H4V in Advanced Solid Tumors

Start date: January 12, 2022
Phase: Phase 1
Study type: Interventional

This study will test the safety of a drug called SGN-B7H4V in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much SGN-B7H4V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe SGN-B7H4V is and if it works to treat solid tumor cancers.

NCT ID: NCT05010629 Active, not recruiting - Metastatic Cancer Clinical Trials

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Start date: September 14, 2021
Phase: Phase 2
Study type: Interventional

This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: - 9-ING-41 (a GSK-3β inhibitor) - Carboplatin chemotherapy

NCT ID: NCT04973683 Recruiting - Clinical trials for Adenoid Cystic Carcinoma

AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Start date: September 30, 2021
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects and possible benefits of AL101 before surgery in treating patients with notch activated adenoid cystic cancer. AL101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving AL101 before surgery may help to control adenoid cystic cancer that has a NOTCH pathway activation.